Market Cap 48.67B
Revenue (ttm) 2.75B
Net Income (ttm) 714.14M
EPS (ttm) N/A
PE Ratio 59.82
Forward PE 54.27
Profit Margin 26.00%
Debt to Equity Ratio 0.00
Volume 821,700
Avg Vol 1,111,612
Day's Range N/A - N/A
Shares Out 163.91M
Stochastic %K 38%
Beta 0.98
Analysts Strong Sell
Price Target $319.92

Company Profile

Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. The company offers Veeva Commercial Cloud comprising Veeva Vault CRM Suite for pharmaceutical and biotechnology companies; Veeva Medical that provides source of medical content across multiple channels and geographies; Veeva PromoMats, an end-to-end content and digital asset management solution; and Veeva Crossix, an analytics pla...

Industry: Health Information Services
Sector: Healthcare
Phone: 925 452 6500
Fax: 925 452 6504
Address:
4280 Hacienda Drive, Pleasanton, United States
HedgeAlerts
HedgeAlerts Nov. 14 at 8:12 AM
Hedge Alert Live - Protect Your Portfolio Contract: $VEEV $290.00 Put · NOV 21, 2025 Exp Entry Price: $10.10 - $10.50 Exit Price Target: $14.70 Profit Margin: +40% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 3:09 AM
$VEEV presents a mixed market context. The last close at $291.7 is below the 30-day moving average (MA30) of $292.6, indicating potential bearish pressure. The relative strength index (RSI) at 48.46 suggests the asset is neither overbought nor oversold, indicating indecision in the market. Directional bias leans slightly bearish due to the price being below MA30 and closer to the 60-day low of $262.85 than the high of $310.5. The 50-day moving average (MA50) at $288.43 also supports this bearish stance. Suggested entry point is $290, just below the MA30. Set a stop-loss at $284, slightly above the MA50 to limit downside risk. Target 1 is $300, approaching the MA30, and Target 2 is $310, near the 60-day high. This plan incorporates current metrics to navigate potential price movements effectively. https://privateprofiteers.com
0 · Reply
sirspanky
sirspanky Nov. 13 at 8:20 PM
$HCTI holding the line at ~$2.19 on a market bloodbath day like an ER triage nurse: calm, caffeinated, and still checking vitals. 🩺😂 Why I’m smirking: • Valuation: Sub-1× EV/S on ~$12–14M rev while health-IT peers often fetch ~2–3.5×. You’re basically paying “contractor” prices for a cloud→data→AI stack (CloudEz / DataEz / Readabl.ai). • Setups: Stockholder call + filing cleanup could tidy the cap table; warrant path = potential runway boost right when hospitals are hunting efficiency. Context tags (not comps, just the theme): $MDRX, $GEHC, $VEEV Bad tape, good patients: hospitals still need margin ops and data plumbing. If you like efficiency plays, this one’s still in the waiting room—pager on. Not advice. 🚑📈
0 · Reply
sirspanky
sirspanky Nov. 13 at 6:41 PM
$HCTI @ ~$2.23 — Undervalued on a red tape + earnings day Why I still like the setup: • Multiple gap: On ~$12–14M rev, HCTI screens sub-1× EV/Sales (≈0.7–0.8× by my math) while Health-IT peers often fetch ~2–3.5×. You’re paying “services” multiples for a cloud → data → AI stack (CloudEz / DataEz / Readabl.ai). • Downturn tailwind: In tougher economies, hospitals must optimize—automation, coding accuracy, data interoperability, and cost analytics get prioritized to protect margins. That’s exactly HCTI’s lane. • Path to re-rate: Clean up the cap table (S-3/warrants), show ARR & margin traction, integrate the HIS/SaaS asset → a move toward even 2.0–2.75× EV/S implies materially higher equity value vs today. For context: premium vertical SaaS like $VEEV, digitized care ops like $GEHC, and provider IT names like $MDRX highlight what the market pays for efficiency. HCTI’s the sleeper version. (Not advice. DYOR.)
1 · Reply
vu_jade
vu_jade Nov. 13 at 3:55 PM
$VEEV buy
0 · Reply
JarvisFlow
JarvisFlow Nov. 13 at 10:01 AM
BMO Capital has updated their rating for Veeva Systems ( $VEEV ) to Market Perform with a price target of 300.
0 · Reply
tdntdn
tdntdn Nov. 13 at 4:10 AM
$VEEV Any catalysts to cause VEEV to rocket higher in the short term? I know earnings are coming up. I'm excited for the long-term prospects and truly believe Veeva is a company that can profit from AI automating functions across their suite of software. On a marketing standpoint, I believe it's now a must have for large pharma and biotechs.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 1:16 AM
$VEEV is currently trading at $299.14, showing a strong upward momentum with an RSI of 61.91, indicating bullish sentiment but nearing overbought territory. The price is above both the 30-day MA of 292.78 and the 50-day MA of 287.48, reinforcing a positive trend. The recent 60-day high of 310.5 suggests potential resistance, while the low of 262.85 provides a solid support level. Directional bias remains bullish due to the price's position relative to the moving averages and the RSI. A suggested entry point could be around $298, with a stop loss set at $292 to manage risk. Targets for this trade could be set at $310 (near the 60D high) and $315, allowing for a favorable risk-reward ratio given the ATR of 6.22. Overall, the market context supports a bullish outlook for $VEEV, making this a strategic entry point. https://privateprofiteers.com
0 · Reply
vu_jade
vu_jade Nov. 12 at 8:03 PM
$VEEV breakout coming!!!!
0 · Reply
bealex32
bealex32 Nov. 12 at 7:33 PM
$VEEV failed breakout retest bounce off of 20 day . If we break resistance 299.63 we should resume breakout . 12 mos price target 340
0 · Reply
Latest News on VEEV
Veeva Systems Inc. (VEEV) Analyst/Investor Day Transcript

Oct 17, 2025, 2:46 AM EDT - 4 weeks ago

Veeva Systems Inc. (VEEV) Analyst/Investor Day Transcript


OpenEvidence and Veeva Announce Open Vista Partnership

Oct 16, 2025, 10:00 AM EDT - 4 weeks ago

OpenEvidence and Veeva Announce Open Vista Partnership


Veeva AI Agents to Be Released Across All Veeva Applications

Oct 14, 2025, 10:03 AM EDT - 4 weeks ago

Veeva AI Agents to Be Released Across All Veeva Applications


Big Money Boost – Veeva Up 975% Since 2015

Oct 10, 2025, 7:01 AM EDT - 5 weeks ago

Big Money Boost – Veeva Up 975% Since 2015


4 Top AI-Powered Healthcare Stocks

Oct 9, 2025, 5:00 AM EDT - 5 weeks ago

4 Top AI-Powered Healthcare Stocks

BSX OPRX ZEPP


How to trade the health care break out

Oct 6, 2025, 2:24 PM EDT - 5 weeks ago

How to trade the health care break out

MCK MRK UNH XBI XLV


Josh Brown's 'Best Stocks in the Market': Veeva Systems

Oct 3, 2025, 2:00 PM EDT - 5 weeks ago

Josh Brown's 'Best Stocks in the Market': Veeva Systems


Veeva to Host Virtual Investor Day on October 16, 2025

Sep 25, 2025, 4:05 PM EDT - 7 weeks ago

Veeva to Host Virtual Investor Day on October 16, 2025


Bristol Myers Squibb Commits to Veeva Vault CRM

Sep 22, 2025, 10:03 AM EDT - 7 weeks ago

Bristol Myers Squibb Commits to Veeva Vault CRM


Gilead Sciences Commits to Veeva Vault CRM

Sep 10, 2025, 10:03 AM EDT - 2 months ago

Gilead Sciences Commits to Veeva Vault CRM


Calls of the Day: Abbvie, Vertex, Veeva and Vistra

Sep 8, 2025, 1:47 PM EDT - 2 months ago

Calls of the Day: Abbvie, Vertex, Veeva and Vistra

ABBV VRTX VST


Veeva Q2: Outpacing Salesforce's "Kill" Switch

Sep 5, 2025, 10:52 AM EDT - 2 months ago

Veeva Q2: Outpacing Salesforce's "Kill" Switch


Veeva Systems: Top-Line Momentum Should Continue To Accelerate

Sep 4, 2025, 10:55 PM EDT - 2 months ago

Veeva Systems: Top-Line Momentum Should Continue To Accelerate


Veeva to Present at Upcoming Investor Conference

Sep 2, 2025, 2:10 PM EDT - 2 months ago

Veeva to Present at Upcoming Investor Conference


More Than 450 Companies Drive Speed to Market with Veeva RIM

Sep 2, 2025, 7:03 AM EDT - 2 months ago

More Than 450 Companies Drive Speed to Market with Veeva RIM


Veeva Systems: Overall, A Good Q2, With Only A Few Minor Issues

Aug 28, 2025, 9:43 AM EDT - 2 months ago

Veeva Systems: Overall, A Good Q2, With Only A Few Minor Issues


Veeva Systems Inc. (VEEV) Q2 2026 Earnings Call Transcript

Aug 28, 2025, 1:34 AM EDT - 2 months ago

Veeva Systems Inc. (VEEV) Q2 2026 Earnings Call Transcript


Veeva Announces Fiscal 2026 Second Quarter Results

Aug 27, 2025, 4:05 PM EDT - 2 months ago

Veeva Announces Fiscal 2026 Second Quarter Results


Leaders Come Together to Advance the Industry at Veeva Summit

Aug 21, 2025, 7:03 AM EDT - 3 months ago

Leaders Come Together to Advance the Industry at Veeva Summit


Survey Finds Medtechs Lack Confidence in Regulatory Data Quality

Jul 30, 2025, 7:03 AM EDT - 3 months ago

Survey Finds Medtechs Lack Confidence in Regulatory Data Quality


The Big 3: ANET, HSY, VEEV

Jul 24, 2025, 12:40 PM EDT - 4 months ago

The Big 3: ANET, HSY, VEEV

ANET HSY


Merck Commits to Veeva Vault CRM

Jul 21, 2025, 10:00 AM EDT - 4 months ago

Merck Commits to Veeva Vault CRM

MRK


Veeva Systems: Growth Momentum Remains Strong

Jul 8, 2025, 11:54 AM EDT - 4 months ago

Veeva Systems: Growth Momentum Remains Strong


Veeva and AWS Expand 10-Year Relationship

Jun 25, 2025, 9:00 AM EDT - 5 months ago

Veeva and AWS Expand 10-Year Relationship

AMZN


Veeva Systems: The Strong Quarter May Be A First Of Many To Come

Jun 18, 2025, 7:35 AM EDT - 5 months ago

Veeva Systems: The Strong Quarter May Be A First Of Many To Come


Veeva Systems: AI And Vault CRM Are Key Long-Term Tailwinds

Jun 5, 2025, 9:15 AM EDT - 5 months ago

Veeva Systems: AI And Vault CRM Are Key Long-Term Tailwinds


Astellas Chooses Veeva Vault CRM as Global Standard

Jun 4, 2025, 7:03 AM EDT - 5 months ago

Astellas Chooses Veeva Vault CRM as Global Standard


Veeva Sees Inflows after Earnings Beat

Jun 4, 2025, 5:13 AM EDT - 5 months ago

Veeva Sees Inflows after Earnings Beat


Veeva Q1: Just Let Your Winner Run

May 31, 2025, 11:59 PM EDT - 5 months ago

Veeva Q1: Just Let Your Winner Run


Veeva to Present at Upcoming Investor Conferences

May 30, 2025, 12:15 PM EDT - 6 months ago

Veeva to Present at Upcoming Investor Conferences


HedgeAlerts
HedgeAlerts Nov. 14 at 8:12 AM
Hedge Alert Live - Protect Your Portfolio Contract: $VEEV $290.00 Put · NOV 21, 2025 Exp Entry Price: $10.10 - $10.50 Exit Price Target: $14.70 Profit Margin: +40% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 3:09 AM
$VEEV presents a mixed market context. The last close at $291.7 is below the 30-day moving average (MA30) of $292.6, indicating potential bearish pressure. The relative strength index (RSI) at 48.46 suggests the asset is neither overbought nor oversold, indicating indecision in the market. Directional bias leans slightly bearish due to the price being below MA30 and closer to the 60-day low of $262.85 than the high of $310.5. The 50-day moving average (MA50) at $288.43 also supports this bearish stance. Suggested entry point is $290, just below the MA30. Set a stop-loss at $284, slightly above the MA50 to limit downside risk. Target 1 is $300, approaching the MA30, and Target 2 is $310, near the 60-day high. This plan incorporates current metrics to navigate potential price movements effectively. https://privateprofiteers.com
0 · Reply
sirspanky
sirspanky Nov. 13 at 8:20 PM
$HCTI holding the line at ~$2.19 on a market bloodbath day like an ER triage nurse: calm, caffeinated, and still checking vitals. 🩺😂 Why I’m smirking: • Valuation: Sub-1× EV/S on ~$12–14M rev while health-IT peers often fetch ~2–3.5×. You’re basically paying “contractor” prices for a cloud→data→AI stack (CloudEz / DataEz / Readabl.ai). • Setups: Stockholder call + filing cleanup could tidy the cap table; warrant path = potential runway boost right when hospitals are hunting efficiency. Context tags (not comps, just the theme): $MDRX, $GEHC, $VEEV Bad tape, good patients: hospitals still need margin ops and data plumbing. If you like efficiency plays, this one’s still in the waiting room—pager on. Not advice. 🚑📈
0 · Reply
sirspanky
sirspanky Nov. 13 at 6:41 PM
$HCTI @ ~$2.23 — Undervalued on a red tape + earnings day Why I still like the setup: • Multiple gap: On ~$12–14M rev, HCTI screens sub-1× EV/Sales (≈0.7–0.8× by my math) while Health-IT peers often fetch ~2–3.5×. You’re paying “services” multiples for a cloud → data → AI stack (CloudEz / DataEz / Readabl.ai). • Downturn tailwind: In tougher economies, hospitals must optimize—automation, coding accuracy, data interoperability, and cost analytics get prioritized to protect margins. That’s exactly HCTI’s lane. • Path to re-rate: Clean up the cap table (S-3/warrants), show ARR & margin traction, integrate the HIS/SaaS asset → a move toward even 2.0–2.75× EV/S implies materially higher equity value vs today. For context: premium vertical SaaS like $VEEV, digitized care ops like $GEHC, and provider IT names like $MDRX highlight what the market pays for efficiency. HCTI’s the sleeper version. (Not advice. DYOR.)
1 · Reply
vu_jade
vu_jade Nov. 13 at 3:55 PM
$VEEV buy
0 · Reply
JarvisFlow
JarvisFlow Nov. 13 at 10:01 AM
BMO Capital has updated their rating for Veeva Systems ( $VEEV ) to Market Perform with a price target of 300.
0 · Reply
tdntdn
tdntdn Nov. 13 at 4:10 AM
$VEEV Any catalysts to cause VEEV to rocket higher in the short term? I know earnings are coming up. I'm excited for the long-term prospects and truly believe Veeva is a company that can profit from AI automating functions across their suite of software. On a marketing standpoint, I believe it's now a must have for large pharma and biotechs.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 1:16 AM
$VEEV is currently trading at $299.14, showing a strong upward momentum with an RSI of 61.91, indicating bullish sentiment but nearing overbought territory. The price is above both the 30-day MA of 292.78 and the 50-day MA of 287.48, reinforcing a positive trend. The recent 60-day high of 310.5 suggests potential resistance, while the low of 262.85 provides a solid support level. Directional bias remains bullish due to the price's position relative to the moving averages and the RSI. A suggested entry point could be around $298, with a stop loss set at $292 to manage risk. Targets for this trade could be set at $310 (near the 60D high) and $315, allowing for a favorable risk-reward ratio given the ATR of 6.22. Overall, the market context supports a bullish outlook for $VEEV, making this a strategic entry point. https://privateprofiteers.com
0 · Reply
vu_jade
vu_jade Nov. 12 at 8:03 PM
$VEEV breakout coming!!!!
0 · Reply
bealex32
bealex32 Nov. 12 at 7:33 PM
$VEEV failed breakout retest bounce off of 20 day . If we break resistance 299.63 we should resume breakout . 12 mos price target 340
0 · Reply
sirspanky
sirspanky Nov. 12 at 5:07 PM
$HCTI Hump Day check-in: $HCTI still looks mispriced. At ~sub-1× EV/S on ~$12–14M rev, we’re valued like a pure services shop while building a cloud→data→AI stack (CloudEz / DataEz / Readabl.AI). That’s a gap. Good news this quarter (why I’m upbeat into P&L): • Balance/Cleanup: Warrant-inducement cash + S-3 on file = longer runway and clearer cap table. • Execution/Partners: New Better × QuantumNexis collaboration (openEHR) = more hospital workflows to land/expand. • Pipeline mix: More SaaS + managed services signals better margin profile into 2025 guidance. What I’m watching on the call: ARR traction, gross margin lift, deal wins from hospital efficiency demand, and timing on the HIS/SaaS front-end layer. If peers like $VEEV / $GEHC / $SNOW command higher bands, the re-rate case for $HCTI is very much alive. Not advice—DYOR. 🚀
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 12:52 AM
$VEEV is currently trading at $299.14, showing a strong upward momentum with an RSI of 61.91, indicating bullish sentiment but nearing overbought territory. The price is above both the 30-day MA of 292.78 and the 50-day MA of 287.48, reinforcing a positive trend. The recent 60-day high of 310.5 suggests potential resistance, while the low of 262.85 provides a solid support level. Directional bias remains bullish due to the price's position relative to the moving averages and the RSI. A suggested entry point could be around $298, with a stop loss set at $292 to manage risk. Targets for this trade could be set at $310 (near the 60D high) and $315, allowing for a favorable risk-reward ratio given the ATR of 6.22. Overall, the market context supports a bullish outlook for $VEEV, making this a strategic entry point. https://privateprofiteers.com
0 · Reply
Gwaadin
Gwaadin Nov. 11 at 4:21 PM
$VEEV nice cross section of new tech with revived health care sector. Chart supportive too. I think it’s being overlooked, but not for long. Small spec for a short-term pop, also building position in Jan 2017 $350 calls.
0 · Reply
vu_jade
vu_jade Nov. 11 at 4:17 PM
$VEEV LOL This is going to fly … Buy any dips
0 · Reply
sirspanky
sirspanky Nov. 11 at 3:31 PM
$HCTI New partnership: QuantumNexis (subsidiary of $HCTI) + Better to roll out openEHR-driven digital health across SE Asia / Middle East / Africa. 🚀 Why this is bullish for $HCTI • Proven platform leverage: Better’s clinical data repo + open data services + low-code speeds hospital deployments; QN adds AI/analytics on top. • Real pipeline: joint pilots at hospitals with a scale path if metrics hit. • Interop moat: openEHR + FHIR = portable data → stickier SaaS revenue. Context comps: $ORCL (Cerner modernization), $MSFT (Azure Health & data fabric), $VEEV (vertical SaaS premium). If HCTI executes, the re-rate case strengthens. (Not advice, just the setup.) Source: https://www.better.care/news/better-and-quantumnexis-partner-to-advance-openehr-driven-digital-health-solutions/
1 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 9 at 11:16 AM
💎 LiquidTheta® Live Actionable Trade Asset: $VEEV Contracts: $VEEV December 18, 2026 $300 Calls Scale in: $41.09- $50.22 Scale out: $159.78-$273.90 Profit Potential : 110% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
QuantitativeTrading_
QuantitativeTrading_ Nov. 7 at 10:21 PM
$GKOS $CYBR $CAMT $VEEV Brown Capital Sells $35 Million in Glaukos Stock After Sharp Sell-Off Brown Capital Management sold 376,359 shares of Glaukos for $34.6M in Q3. The sale represented about 1.4% of the fund's 13F assets. It retains 762,760 shares valued at $62.2M.
0 · Reply
sirspanky
sirspanky Nov. 7 at 4:58 PM
$HCTI TI Shareholder Call — What I’m Listening For 👇 Revenue & margin mix. Are we still tracking ~$12–14M rev and improving gross margin as cloud→data→AI (CloudEz / DataEz / Readabl.AI) grows vs legacy services? Pipeline/logos. New hospital wins, renewals, or partner co-sells (AWS/Azure) that expand the 100+ site footprint. LOI/HIS SaaS update. Timing, go-to-market, and how the front-end CX/agent layer plugs into the platform. Cap table cleanup. Status of S-3, stockholder approvals, and the path for $3.X warrants (potential ~$4.X.3M cash runway boost). Profitability path. OpEx discipline, cash burn, and any KPI targets (ARR, backlog, net retention). Why it matters: HCTI still screens sub-1× EV/Sales vs Health-IT peers at ~2–3.5×. Execution + clarity can force a re-rate. Context tickers: $MDRX $GEHC $VEEV (bigger names riding the same hospital digitization wave). Not advice.
1 · Reply
sirspanky
sirspanky Nov. 6 at 2:42 PM
$HCTI at $2.73 into earnings = still undervalued vs what it’s building. Why the “real value” looks higher: • Sub-1× EV/Sales on ~$12–14M rev (by my math ~0.7–0.8×) while health-IT micros often fetch ~2–3.5×. • Platforms + customers: CloudEz / DataEz / Readabl.AI + Ezovion serving 100+ provider sites (must-run hospital spend = sticky in any tape). • Cleanup/catalysts: shareholder vote + S-3 could tidy the cap table; if $3.X warrants eventually exercise, that’s ~$4.3M runway to scale. Implied band: a simple re-rate toward 2–2.75× EV/S on ~$13M suggests ~$4.8–$6.2 on the current share count (higher if rev lands at the top end). Earnings/KPIs are the spark. Context tickers (not 1:1 comps): $CPSI (community hospitals), $GEHC (digitized care), $VEEV (vertical SaaS premium). Undiscovered + operating leverage = compelling risk/reward. Not advice. 🚀
0 · Reply
sirspanky
sirspanky Nov. 5 at 8:10 PM
$HCTI back green at $2.X .67 — still looks like the undiscovered hospital-IT play. Why I’m pumped: • Value gap: On ~$12–14M rev, HCTI screens sub-1× EV/S, while health-IT/vertical SaaS names often fetch ~2–3.5×. Paying “services” pricing for a cloud→data→AI stack (CloudEz / DataEz / Readabl.AI + Ezovion). • Catalyst lane: Shareholder vote + S-3 cleanup sets the table; if $3.X warrants get exercised, that’s ~$4.X.3M potential runway while hospital/HIS momentum builds (100+ provider sites). • Bear-tape moat: Hospitals are must-run; efficiency software gets prioritized when budgets tighten. Context (not 1:1 comps): $ORCL (Cerner rails), $VEEV (premium vertical SaaS), $GEHC (digitized care). If this re-rates even toward a plain-vanilla 2–2.75× EV/S, the math points up from here. Eyes on a $3.X re-test with volume. Not advice—just the setup. 🚀
0 · Reply
vu_jade
vu_jade Nov. 4 at 7:40 PM
$VEEV looking for all time high after their 11/20 Report
0 · Reply
sirspanky
sirspanky Nov. 4 at 4:44 PM
$HCTI looks like a bear-market sleeper for hospital IT folks. Why it fits the moment: • Hospitals are must-run in any economy; downturns push CFOs to buy efficiency, not shiny toys. • Spend shifts to Opex/SaaS & managed services that cut labor hours, boost uptime, and speed billing. • Compliance (HIPAA/Cures, DR/BCP, ransomware readiness) = sticky, non-discretionary budgets. What HCTI sells into that: CloudEz (secure multi-cloud/DR/SOC) → lower infra cost + uptime DataEz (analytics/AI workbenches) → faster ops insights Readabl.AI (fax/docs→structured data) → revenue cycle speed Ezovion/HIS front-end for throughput Valuation kicker: screens sub-1× EV/S on ~$12–14M rev while health-IT micros often trade ~2–3.5×. If you watch $CPSI, $GEHC, or $VEEV for hospital efficiency themes, HCTI is the under-the-radar version riding the same secular shift. Not advice.
0 · Reply